FANASTOMIG
UNII 1GCR6YY9NI

Substance Identification & Data

This profile provides standardized clinical and technical data for Fanastomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 1GCR6YY9NI.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2761795-00-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

1GCR6YY9NI

CAS Registry Number

2761795-00-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FANASTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203056

National Cancer Institute reference terminology for clinical and research data.

INN ID

12694

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Fanastomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Fanastomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Fanastomig

Common Names & Synonyms

Immunoglobulin L-kappa-H-gamma1_G1(VH-CH1-h)_L-kappa dimer, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)] and anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody, bispecific

[L-kappa-H-gamma1 heavy chain anti-LAG3 and anti-PDCD1 (1-665) [L-kappa anti-LAG3 (1-214) [V-KAPPA Musmus/Homsap (Mus musculus IGKV9-124*01 (88.4%) -IGKJ5*01 (91.7%) A120>Q (100)/Homo sapiens IGKV1-16*01 (84.2%) -IGKJ2*01 (90.9%) I126>L (106), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108-214)] -H-gamma1 heavy chain anti-PDCD1 (215-665) [VH (Homo sapiens IGHV3-48*02 (91.8%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.14] (240-247.265-272.311-324)) (215-335)-Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, IGHG1v14 CH2 A1.3, A1.2 (CH1 R120>K (432) (336-433), hinge 1-15 (434-448), CH2 L1.3>A (452), L1.2>A (453)(449-558), CH3 E12 (574), M14 (576) (559-663), CHS (664-665)) (336-665)]]; (214-216')-disulfide with G1(VH-CH1-h) light chain anti-LAG3 (1'-216') [VH Musmus/Homsap (Mus musculus IGHV14-4*01 (86.6%) -IGHD -IGHJ4*01 (92.3%) S123>T (108')/Homo sapiens IGHV1-69-2*01 (72.9%) -IGHD -IGHJ6*01 (87.5%), CDR-IMGT [8.8.6] (26'-33'.51'-58'.97'-102')) (1'-113') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120 (CH1 R120>K (210') (114'-211'), hinge 1-5 (212'-216')) (114'-216')]; (438-214''')-disulfide with L-kappa light chain Homo sapiens anti-PDCD1 (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-33*01 (86.3%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.51'''-53'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (153'''), V101 (191''') (108'''-214''')]; dimer (444-444'':447-447'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

fanastomig [INN]

External Clinical & Regulatory Resources

Previous UNII1GCK3968PS

Next UNII1GCT2G09AN